Pharmaceutical Technology7d
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth
The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.
The Financial Express5d
AstraZeneca’s Fasenra set to revolutionise COPD treatment as Phase III data builds anticipation
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
MedPage Today25d
Environmentally Friendlier COPD Inhaler May Also Be More Effective
Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first moderate or severe COPD exacerbation (HR 1.09, 95% CI 1.04-1.14 ...
Hosted on MSN24d
Environmentally Friendlier COPD Inhaler May Also Be More Effective
There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...
Yahoo Finance7d
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth
Key drivers include Breztri Aerosphere (budesonide ... to target specific inflammatory pathways in COPD, a space previously dominated by inhaled therapies. AstraZeneca’s Fasenra, an IL-5 ...
2minutemedicine.com16d
Different single inhaler triple therapies appear to have similar clinical outcomes for chronic obstructive pulmonary disease
In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...
verywellhealth8d
Knowing Inhaler Colors and What They Mean
It's also important to remember that some inhalers are meant only for people diagnosed with chronic obstructive pulmonary disease (COPD) and don't treat asthma. These medications include: In many ...